Susquehanna International Group, LLP Arca Biopharma, Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$1.7 - $2.05 $22,100 - $26,649	-13,000 Reduced 45.45%	15,600 $26,000
Q3 2023 Nov 14, 2023	SELL	$2.01 - $2.07 $24,923 - $25,667	-12,400 Reduced 30.24%	28,600 $57,000
Q2 2023 Aug 11, 2023	SELL	$1.94 - $2.11 $18,624 - $20,256	-9,600 Reduced 18.97%	41,000 $83,000
Q1 2023 May 16, 2023	BUY	$1.99 - $2.55 $9,950 - $12,750	5,000 Added 10.96%	50,600 $100,000
Q4 2022 Feb 14, 2023	SELL	$1.86 - $2.44 $74,958 - $98,332	-40,300 Reduced 46.92%	45,600 $108,000

Q3 2022 Nov 14, 2022	SELL	$2.13 - $2.51 $75,189 - $88,602	-35,300 Reduced 29.13%	85,900 $177,000
Q2 2022 Aug 15, 2022	BUY	$2.2 - $2.53 $137,940 - $158,631	62,700 Added 107.18%	121,200 $302,000
Q1 2022 May 16, 2022	BUY	$1.77 - $2.49 $16,107 - $22,659	9,100 Added 18.42%	58,500 $135,000
Q4 2021 Feb 14, 2022	BUY	$2.15 - $2.97 $77,830 - $107,514	36,200 Added 274.24%	49,400 $106,000
Q1 2021 May 17, 2021	BUY	$3.48 - $5.3 $45,936 - $69,960	13,200 New	13,200 $48,000

7.23M

54.7K

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Market Cap $55.2M
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.